NasdaqGS:ALNYBiotechs
Alnylam Pharmaceuticals (ALNY) Profitability Milestone Reinforces Bull Case Ahead of Forecasted 52% Earnings Growth
Alnylam Pharmaceuticals (ALNY) achieved profitability over the past year, with average annual earnings growth of 27.5% over the last five years. Looking ahead, forecasts anticipate earnings growth of 52% per year and revenue rising by 25.2% annually, both well ahead of US market benchmarks. With recently improved net profit margins, high-quality earnings, and a discounted cash flow valuation that suggests shares are trading below fair value, investors may see this as a compelling growth...